Merck & Co (MRK) last issued guidance on April 30, 2026 for fiscal year 2026. The company guided earnings per share in the range of $5.04 - $5.16, compared to a consensus EPS estimate of $5.07. Merck & Co also guided revenue in the range of $65.80B - $67.00B for the period.
Compared to prior guidance, Merck & Co maintained its EPS outlook from a previous range of $5.00 - $5.15. On the revenue side, the company maintained its revenue forecast from a prior range of $65.50B - $67.00B.
Merck & Co has issued 16 guidance updates between July 28, 2022 and April 30, 2026. During this period, the company raised its outlook 3 times and lowered it 5 times, providing investors with insight into management's evolving expectations.
Review all historical guidance issued by Merck & Co, including EPS and revenue forecasts across quarterly and annual periods.
The most recent guidance for Merck & Co (MRK) was reported on April 30, 2026 for the fiscal year 2026. The company provided earnings per share guidance in the range of $5.04 to $5.16, compared to the estimated EPS of $5.07. Additionally, Merck & Co forecasted revenue between $65.80B and $67.00B for the period.
Merck & Co (MRK) guided EPS in the range of $5.04 to $5.16 for the fiscal year 2026. The consensus analyst EPS estimate is $5.07.
Merck & Co (MRK) guided revenue in the range of $65.80B to $67.00B for the fiscal year 2026.
Merck & Co (MRK) maintained its EPS guidance from a prior range of $5.00 - $5.15 to $5.04 - $5.16 for the fiscal year 2026.
Merck & Co (MRK) last issued guidance on April 30, 2026 for the fiscal year 2026.